Small Group Intervention Reduced Distress Related to Adjuvant Endocrine Therapy

By Leah Lawrence - Last Updated: August 26, 2022

The telehealth intervention STRIDE (Symptom-Targeted Randomized Intervention for Distress and Adherence to Adjuvant Endocrine Therapy) that focused on symptom management, adherence, and distress had promising efficacy for patients taking adjuvant endocrine therapy (AET) after breast cancer.

A study assessing STRIDE randomly assigned 100 patients reporting difficulty with AET to either STRIDE or a medication monitoring control group. Patients assigned to STRIDE has six weekly small-group videoconferencing sessions and two individuals calls.

The researchers defined feasibility of the intervention as more than 50% of eligible patients enroll, more than 70% complete the 12-week assessment, and more than 70% of STRIDE patients completed four or more of the six sessions. The results were published in Cancer.

The majority (92%) of patients completed the 12-week assessment and 86% completed four or more of the six STRIDE sessions.

Compared with patients assigned to medication monitoring, those assigned to STRIDE reported less symptom distress (P=.007) and better self-management of AET symptoms, coping, quality of life (QOL), and mood. Patients assigned to STRIDE also reported less symptom distress related to hot flashes and better ability to use stress coping skills.

No difference in AET satisfaction or adherence was reported.

“These findings are notable, given the length of time that patients take these medications, struggle with side effects, and experience deteriorations in QOL,” the researchers wrote. “These  findings are also  critical given that symptom distress, mood, and QOL are associated with adherence to oral anticancer treatment.”


A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial